SYRS

Syros Pharmaceuticals Inc

SYRS.US syros.com
0.00
+0.00 (+0.00%)
USD · PINK
52-week range
0.00
0.01
Trading at 4% of the 52-week range
Market Cap
10.73K
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-0.42
Div. Yield
N/A
% Institutions
9.62%
% Insiders
0.075%

1 Year

-75.0%

3 Year

-100.0%

10 Year

-100.0%
Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Company Information

Company Name
Syros Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
PINK
ISIN: US87184Q1076
CIK: 0001556263
CUSIP: 87184Q107
Currency: USD
Full Time Employees: 68
Phone: 617 744 1340
Website: syros.com
Fiscal Year End: December
IPO Date: Jun 30, 2016
Description:

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Address:

35 CambridgePark Drive, Cambridge, MA, United States, 02140

People

Directors & Officers

Name Title Year Born
Dr. James E. Bradner M.D. Founder 1972
Dr. Nathanael S. Gray Ph.D. Scientific Founder & Member of Scientific Advisory Board NA
Matthew Foster Chief Restructuring Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 02, 2024 Nancy A Simonian N/A Sale 37.07K $0.27 $10.01K
Nov 25, 2024 Nancy A Simonian N/A Sale 134.71K $0.27 $36.37K
Sep 12, 2024 Jason Haas N/A Purchase 45.34K $1.68 $76.18K
Sep 10, 2024 Conley Chee N/A Purchase 50.00K $1.51 $75.50K
Sep 10, 2024 Jason Haas N/A Purchase 35.36K $1.55 $54.81K
Jun 28, 2024 Richard A Young N/A Sale 34.84K $5.12 $178.37K
Apr 02, 2024 David Roth N/A Sale 150.00 $4.98 $747.00

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Bain Capital Life Sciences Investors, LLC 2.75M Dec 31, 2024 10.25% $0.07 0.00%
BlackRock Inc 277.25K Dec 31, 2024 1.03% $0.00 5.99%
Vanguard Group Inc 268.15K Dec 31, 2024 1.00% $0.00 -71.87%
Omega Fund Management LLC 251.27K Dec 31, 2024 0.94% $0.05 0.00%
Geode Capital Management, LLC 196.25K Dec 31, 2024 0.73% $0.00 -4.12%
Affinity Asset Advisors, LLC 150.00K Dec 31, 2024 0.56% $0.00 0.00%
Citigroup Inc 139.22K Dec 31, 2024 0.52% $0.00 20,165.50%
Qube Research & Technologies 122.17K Dec 31, 2024 0.46% $0.00 57.21%
TWO SIGMA SECURITIES, LLC 107.74K Dec 31, 2024 0.40% $0.00 0.00%
Renaissance Technologies Corp 96.04K Dec 31, 2024 0.36% $0.00 -0.41%
HRT FINANCIAL LLC 87.54K Dec 31, 2024 0.33% $0.00 0.00%
XTX Topco Ltd 81.46K Dec 31, 2024 0.30% $0.00 182.51%
State Street Corp 69.43K Dec 31, 2024 0.26% $0.00 0.00%
Jane Street Group LLC 52.92K Dec 31, 2024 0.20% $0.00 0.00%
Two Sigma Investments LLC 48.86K Dec 31, 2024 0.18% $0.00 71.59%
UBS Group AG 45.05K Dec 31, 2024 0.17% $0.00 169.31%
Northern Trust Corp 40.81K Dec 31, 2024 0.15% $0.00 0.00%
1492 Capital Management, LLC 39.24K Dec 31, 2024 0.15% $0.00 0.00%
Virtu Financial LLC 32.79K Dec 31, 2024 0.12% $0.00 67.05%
Baader Bank INC 22.09K Dec 31, 2024 0.08% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Institutional Extnd Mkt Idx Tr 257.64K 0.96% ▲ 0.00% Jan 31, 2025
2 Fidelity Extended Market Index 97.61K 0.36% ▼ 1.08% Jan 31, 2025
3 iShares Micro-Cap ETF 45.83K 0.17% ▲ 0.00% Feb 28, 2025
4 Extended Equity Market Fund K 44.75K 0.17% ▼ 1.36% Dec 31, 2024
5 Fidelity Total Market Index 39.83K 0.15% ▲ 0.00% Jan 31, 2025
6 Fidelity Series Total Market Index 23.73K 0.09% ▲ 0.00% Jan 31, 2025
7 Northern Trust Extended Eq Market Idx 22.60K 0.08% ▲ 0.00% Dec 31, 2024
8 NT Ext Equity Mkt Idx Fd - L 22.60K 0.08% ▲ 0.00% Dec 31, 2024
9 NT Ext Equity Mkt Idx Fd - NL 16.81K 0.06% ▲ 0.00% Dec 31, 2024
10 NT Ext Equity Mkt Idx Fd - DC - NL - T2 13.33K 0.05% ▼ 1.62% Dec 31, 2024

Financial Highlights

Market Cap: $10.73K
EBITDA: $-110.18M
PEG Ratio: $0.00
Book Value: $-0.42
Earnings/Share: $-3.07
Profit Margin: 0.00%
Operating Margin: -28,891.71%
ROA (TTM): -59.88%
ROE (TTM): -776.96%
Revenue (TTM): $386.00K
Revenue/Share (TTM): $0.01
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -3.30%

Valuation Metrics

Enterprise Value: $1.96M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 26.83M
Shares Float: 26.83M
% Insiders: 0.075%
% Institutions: 9.62%
Short % Float: 3.81%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$9.94M
Cost of Goods Sold
adjust
$-2.25M
Gross Profit
subtotal
$7.68M
SG&A
adjust
$-28.28M
R&D
adjust
$-108.15M
Operating Income
subtotal
$-128.99M
Other / Non-Operating Items
adjust
$-35.59M
Net Income
subtotal
$-164.57M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SYRS.US!